Thiazolidinedione compounds: a patent review (2010 – present)

Bibliography

• Chang E, Park CY, Park SW, et al. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;27:517-24
   Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32:S62-7
   PubMed Web of Science ®Google Scholar
• Gisela W. Insulin and insulin resistance. Clin Biochem Rev 2005;26(2):19-39
   PubMedGoogle Scholar
• Gilberto PF, Claudio M, Wong ML, et al. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab 2012;16(9):549-55
   Google Scholar
• Florentina GL, Oana MD, Profire L, et al. The synthesis and the biological evaluation of new thiazolidin-4-one derivatives containing a xanthine moiety. Molecules 2013;18:9684-703
   PubMed Web of Science ®Google Scholar
• Bazelier MT, Vestergaard P, Leufkens HG. Use of thiazolidinediones and risk of bladder cancer: disease or drugs? Curr Drug Saf 2013;8(5):364-70
   PubMedGoogle Scholar
• Hsiao FY, Hsieh PH, Huang WF. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. Drug Saf 2013;36(8):643-9
   PubMed Web of Science ®Google Scholar
• Cho DH, Lee EJ, Kwon KJ. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem 2013;126(5):685-95
   PubMed Web of Science ®Google Scholar
• Asija R, Kaur M, Sangeeta A, et al. Formulation and evaluation of fast dissolving tablet of Pioglitazone. Res J Pharm Technol 2012;5:817-21
   Google Scholar
• Tseng CH. Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 2. J Diabetes 2014;6(5):448-50
   PubMed Web of Science ®Google Scholar
• Shukla R, Kalra1 S. Pioglitazone: indian perspective. Indian J Endocrinol Metab 2011;15(4):294-7
   PubMedGoogle Scholar
• Tanoue Y, Murakawa Y, Mizuno Y. Sustained-release preparation. WO058409; 2013
   Google Scholar
• Brew J, Bannister RM. Cancer drug and uses. WO108571; 2014
   Google Scholar
• Hefny ALS. Potentiometric device and method selective for Pioglitazone. US0174952; 2014
   Google Scholar
• Barranco HG, Arzola PM. Pharmaceutical composition comprising a meglitinide and a thiazolidinedione, and use thereof. WO091430; 2014
   Google Scholar
• Jeong HJ. Method for diagnosing selectively malignant tumor by differentiating malignant tumor and inflammation in f-18 FDG positron emission tomography using Pioglitazone. KR068817A; 2013
   Google Scholar
• Harmon PA, John CT. Pharmaceutical compositions that inhibit disproportionation. WO055609A1; 2013
   Google Scholar
• Balkrishnan R, Arondekar BV, Camacho FT, et al. Comparisons of Rosiglitazone versus Pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus. Clin Ther 2007;29(6 Pt 1):1306-15
   Google Scholar
• Ye W, Zhang X, Xiao Y, et al. Treatment of eye diseases in the preparation of a medicament for the PPAR-gamma ligand. CN103893177A; 2014
   Google Scholar
• Guangyan W. Novel capsule filled with Rosiglitazone solid preparation and metformin solid preparation. CN103356502; 2013
   Google Scholar
• Meditop G. A heart side effect diminution of Rosiglitazone for treatment for Type I and Type II diabetes. HU000545; 2011
   Google Scholar
• Conget MP, Contador MD. Composition comprising a glucocorticoid and a thiazolinedione for inducing complete adipogenic differentiation of mammalian stem cells. WO071459; 2013
   Google Scholar
• Gupta S, Saini V. Composition and method of spirulina with Pioglitazone or Rosiglitazone and its synergistic effect. INDE02129; 2011
   Google Scholar
• Yongliang G, Bingzhang W. Liquid medicine composition of Rosiglitazone. CN102552140; 2013
   Google Scholar
• Ya W, Songlin Z, Chenggong Z, et al. Method for preparing Rosiglitazone tartrate. CN102532122; 2012
   Google Scholar
• Agrawal R, Jain P, Dikshit SN, et al. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (gamma) agonist. Mini Rev Med Chem 2012;12(2):87-97
   PubMed Web of Science ®Google Scholar
• Bente R, Henriksen K, Kumar R, et al. Balaglitazone compositions and methods. US0109620; 2013
   Google Scholar
• Dr. Reddy’s Research Foundation. New pharmaceutical composition and the process for its preparation. JP5524435B2; 2014
   Google Scholar
• Henry RR. Effects of Troglitazone on insulin sensitivity. Diabet Med 1996;13:S148-50
   Web of Science ®Google Scholar
• Retired drugs: failed blockbusters, homicidal tampering, fatal oversights, wired.com
   Google Scholar
• Cohen JS. Risks of troglitazone apparent before approval in USA. Diabetologia 2006;49(6):1454-5
   PubMed Web of Science ®Google Scholar
• Marta S, Pitre M, Nadeau A, et al. Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats. Metabolism 2003;52(8):978-86
   PubMed Web of Science ®Google Scholar
• Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by Troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20
   PubMed Web of Science ®Google Scholar
• Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9
   PubMed Web of Science ®Google Scholar
• Moon JH, Cha BS. Method for treatment of diseases caused by accumulation of beta-amyloids in brain parenchyma with low concentration thiazolidinedione derivatives. WO022139; 2013
   Google Scholar
• Baghdoyan S, Peschanski M, Laustriat D, et al. Methods and compositions comprising AMPK activator (Metformin/Troglitazone) for the treatment of myotonic dystrophy type 1 (DM1). US0187595; 2014
   Google Scholar
• Kalayoglu MV, Singer MS. Methods and compositions for locally increasing body fat. US8778981; 2014
   Google Scholar
• Hammock BD, DE TBM, Vaughan DE, et al. Methods and compositions for treatment of obesity-related diseases. US0065756; 2011
   Google Scholar
• Amans D, Bellosta V, Dacquet C, et al. Synthesis and evaluation of new polyenic compounds as potential PPARs modulators. Org Biomol Chem 2012;10(30):6169-85
   PubMed Web of Science ®Google Scholar
• Amato AA, Rajagopalan S, Lin JZ, et al. GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain. J Biol Chem 2012;287(33):28169-79
   PubMed Web of Science ®Google Scholar
• Ernesto F, Baltimore MD, Yoshiaki K, et al. Inhibitors of plasmepsins. US 7560482; 2009
   Google Scholar
• Sohma Y, Hayashi YIT, Matsumoto H, et al. Development of water-soluble prodrugs of the hiv-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. J Med Chem 2003;46:4124-35
   PubMed Web of Science ®Google Scholar
• Jasmin L, Kamila AM, Isolmar S, et al. Druggable in Plasmodium falciparum? Int J Cell Biol. 2013.2013:13
   Google Scholar
• Freire E, Nezami A, Kiso Y. Inhibitors of plasmepsins. WO2002/074719; 2002
   Google Scholar
• Michael PM, Stephen JB, Joseph JL, et al. Network™ Modeling identifies common and unique mechanisms for sensitivity to the PI3K inhibitor GSK1059615 and the AKT inhibitor GSK690693. Mol Cancer Ther 2009;8(12 Suppl):C58
   Google Scholar
• Sengupta S, Kulkarni A, Rao P, et al. Compositions for treating cancer and methods for making the same. WO188763; 2013
   Google Scholar
• Jimeno A, Hausman DF, Peterson S, et al. Methods for treating oncovirus positive cancers. WO118978; 2012
   Google Scholar